Metastatic Renal Cell Carcinoma Clinical Trials

210 clinical trials for Metastatic Renal Cell Carcinoma across international registries, including 29 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma — RECRUITING · PHASE2
• A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) — RECRUITING · PHASE2
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours — RECRUITING · PHASE1
• Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors — RECRUITING · PHASE2
• Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases — RECRUITING · PHASE2
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
• Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma — RECRUITING · PHASE4
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — RECRUITING · PHASE1
• Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial — RECRUITING · PHASE2
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain — RECRUITING · PHASE3
• A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) — RECRUITING · PHASE1
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
• Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC — RECRUITING · PHASE2
• Drug Screening Using Novel IMD in Renal Cell Carcinoma — RECRUITING · PHASE1
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial — RECRUITING · NA
• Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations — RECRUITING · PHASE2
• A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma — RECRUITING · PHASE2
• A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases — RECRUITING · PHASE2
• Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma — RECRUITING · PHASE2
• International Multicentric Study ARON-1 — RECRUITING
• Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer — RECRUITING · PHASE2
• PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk — RECRUITING · PHASE2
• Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial — RECRUITING · PHASE3
• Measuring Oncological Value of Exercise and Statin — RECRUITING · PHASE3
• Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib — RECRUITING
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer — RECRUITING · PHASE1
• Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients — RECRUITING · PHASE2
• Urine Omics Predicting IO Therapy Responses in mRCC Patients — RECRUITING
• A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT — TERMINATED · PHASE2
• A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination with Sunitinib compared with Sunitinib alone as first line treatment for patients with metastatic renal-cell carcinoma (mRCC). — COMPLETED · PHASE2
• Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma — COMPLETED · PHASE2
• A clinical trial of axitinib plus PF-04856884 or axitinib alone for patients with metastatic renal cancer who have already been treated with an anti-VEGF agent. — TERMINATED · PHASE2
• Retreatment with sunitinib in patients with metastatic (spread) kidney cancer. — TERMINATED · PHASE2
• A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) — ACTIVE_NOT_RECRUITING · PHASE2
• A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk — TERMINATED · PHASE3
• Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer — COMPLETED · PHASE2
• Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer — NOT_YET_RECRUITING · PHASE1
• Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy — ACTIVE_NOT_RECRUITING · PHASE3
• Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. — ACTIVE_NOT_RECRUITING
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study — ACTIVE_NOT_RECRUITING · PHASE3
• Cancer and Blood Pressure Management, CARISMA Study — ACTIVE_NOT_RECRUITING · NA
• Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) — ACTIVE_NOT_RECRUITING · PHASE2
• SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC). — COMPLETED
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA — TERMINATED · PHASE3

Refine this search